Skip to content

A Study to Evaluate the Efficacy and Safety of TBN For Treatment of Patient With Amyotrophic Lateral Sclerosis

A Multiple Center, Randomized, Double-Blinded and Placebo-Controlled Study to Evaluate the Efficacy and Safety of TBN for Treatment of Patient With Amyotrophic Lateral Sclerosis

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000039689
Enrollment
Unknown
Registered
2020-11-05
Start date
2020-11-15
Completion date
Unknown
Last updated
2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Interventions

experimental group 1:TBN tablets 600 mg
experimental group 2:TBN tablets 1200 mg

Sponsors

Peking University Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Age 45 to 70 years old (inclusive), gender is not limited; 2) Diagnosis in accordance with ALS Revised Criteria of the World Federation of Neurology, 1998, diagnosis of definite or probable ALS. 3) Subjects has a disease duration of 2 points when enroll, and the respiratory function in ALSFRS-R is 4 points; 5) ALSFRS-R score decreases by 1-4 points (inclusive) during the screening period; 6) Forced Vital Capacity (%FVC) >= 80% before randomization; 7) Subjects must understand and be will to compliant with the study rules, voluntarily participate, and sign an informed consent form (informed consent form is voluntarily signed by the subject himself/herself or his/her legal representative).

Exclusion criteria

Exclusion criteria: 1) Patients with familial amyotrophic lateral sclerosis(according to family history) 2) Patients with obvious cognitive impairment (MMSE scale: illiterate group 8 years) 3 times ULN, or other identified liver diseases such as acute and chronic hepatitis, cirrhosis, etc.; 6) From the screening period, in the past 6 months, patients come up with acute myocardial infarction or interventional therapy, heart failure (NYHA CLASS III-IV); 7) Combined with malignant tumors or other systematic diseases such as digestive system disease and hematological system diseases. 8) Patients who are allergic to the investigational product or tetramethylpyrazine; 9) Female patients in pregnancy or lactation; 10) Having participated in other clinical studies within 30 days before randomization, or is participating in other clinical studies; 11) Patients that the investigator considers unsuitable for participation in the study.

Design outcomes

Secondary

MeasureTime frame
Grip strength;FVC;ALSAQ-40;Time to reach the end event;

Primary

MeasureTime frame
ALSFRS-R;

Countries

China

Contacts

Public ContactDongsheng Fan
dsfan@sina.com+86 10-82266699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026